Favorable response to mTOR inhibition in a young patient with unresectable fibrolamellar carcinoma of the liver

Abstract

Fibrolamellar carcinoma (FLC) is a distinct and rare liver cancer typically occurring in young adults in the non-cirrhotic liver. Its rarity impedes evidence-based treatment guidelines derived from large clinical trials and thus case reports describing successful experimental treatments are an important instrument in improving FLC-patient care. We report one patient with end-stage FLC at time of diagnosis with a significant reduction in tumor mass and improvement of quality of life upon third-line palliative treatment with the mTOR inhibitor everolimus. This article is protected by copyright. All rights reserved.

http://ift.tt/2F1uOgw